Business Context and Reporting Period
This Form 8-K is a current report filed by Novus Therapeutics, Inc. (not Eledon Pharmaceuticals, Inc.) on December 10, 2020, regarding events occurring on December 8, 2020. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol NVUS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and compensatory arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of June Lee, M.D. to the Board of Directors. The Board determined Dr. Lee qualifies as an "independent" director under Nasdaq rules. She has been appointed to serve on the Compensation Committee and the Nominating & Governance Committee.
Guidance, Outlook, and Unusual Items
- Compensatory Arrangement: In connection with her appointment, Dr. Lee was granted an option to purchase up to 40,000 shares of Common Stock at an exercise price of $19.74 per share.
- Vesting Schedule: The option vests in two tranches: 20,000 shares on the first anniversary of the grant date and 20,000 shares on the second anniversary.
- Indemnification: Dr. Lee entered into the company's standard indemnification agreement, which may require Novus to cover certain expenses, including attorneys' fees, judgments, fines, and settlement amounts arising from her service as a director.
- Relationships: The filing states there are no family relationships between Dr. Lee and existing executive officers or directors, and no undisclosed arrangements regarding her appointment.
Investor Verification Checklist
- Verify the independence status of June Lee, M.D. under current Nasdaq Marketplace Rules.
- Confirm the total number of outstanding stock options and the impact of the new 40,000-share grant on potential dilution.
- Review the specific terms of the standard indemnification agreement to understand potential liability exposure.
- Check subsequent filings for any changes to the Board composition or committee assignments.